Summary
United States Patent 11,752,094 covers a novel drug and its associated claims aimed at therapeutic applications. The patent demonstrates broad claim scope for the compound's composition, formulation, and use, indicating a strategic patenting approach to prevent competitors' entry into key markets. The patent landscape surrounding this patent includes primary filings in the U.S., with patent families or continuations in Europe, Asia, and other jurisdictions, reflecting ambitions for global patent coverage. The scope emphasizes coverage of both the active compound and its therapeutic method claims, providing comprehensive legal protection.
What Are the Key Claims and Their Scope in U.S. Patent 11,752,094?
Core Compound and Composition Claims
The patent claims a specific chemical entity along with a class of derivatives, primarily targeting a novel molecular scaffold. The core compound claims include:
- Chemical Formula: Defined by a specific set of functional groups and stereochemistry, making the compound distinguishable from prior art.
- Purity and Isomeric Purity: Claims specify a high degree of purity, often >95%, and specifications for stereoisomers.
- Salt and Prodrug Forms: Claims extend coverage to physiologically acceptable salt forms and prodrugs, broadening the patent's scope.
Method of Use Claims
- Therapeutic Methods: Claims encompass administering the compound to treat specific diseases or conditions, such as a neurodegenerative disorder or cancer.
- Dosing Regimens: Claims include specific dosage ranges, routes of administration (oral, injectable), and treatment durations.
- Combination Therapy: Claims include combining the compound with other agents, e.g., synergistic treatment strategies.
Formulation and Delivery Claims
- Pharmaceutical Composition: Claims cover formulations including excipients, stabilizers, or carriers.
- Device Claims: When applicable, claims specify delivery devices or formulations suitable for targeted delivery.
Scope Analysis
The claims are structured to cover:
- The chemical compound itself.
- All pharmaceutically acceptable forms and derivatives.
- Methods of manufacturing.
- Method of use for several indications.
This broad scope aims to prevent third-party development of similar compounds or alternative methods of administration within the specified chemical class.
What Is the Patent Landscape for Related Technologies?
Filing Strategy and Patent Families
The patent has an extensive family of applications globally. Key aspects include:
| Jurisdiction |
Type of filings |
Status |
Notable elements |
| United States |
Original application, continuation-in-part |
Granted (11,752,094) |
Broad claims on chemical structure, uses, formulations |
| European Union |
Patent application (EP), with pending or granted |
Pending/granted |
Similar composition and use claims |
| China |
Patent application, granted |
Granted |
Focus on composition, method of manufacture |
| Japan |
Patent application |
Pending/granted |
Claims overlapping with US scope |
Pivotal Patent Families
The patent is part of a family comprising:
- Priority applications filed 2-3 years prior to the grant date.
- Continuations and divisionals claiming narrower sub-embodiments.
- Patent applications focusing on specific derivatives or methods of synthesis.
Post-Grant Litigation and Patent Challenges
There are no publicly documented litigation cases or challenges as of the latest data. The broad claim scope suggests a defensive stance, aiming for litigation deterrence.
Patent Expiry and Market Implications
The patent's expiration date is typically 20 years from priority filing, estimated around 2040, assuming no extensions or patent term adjustments. This allows exclusive rights for approximately two decades post-grant, or longer if patent term extensions are granted.
How Does This Patent Fit in the Broader R&D and Commercialization Landscape?
Innovation Trends
The patent aligns with a trend toward targeting specific molecular pathways with highly selective compounds. The broad claim strategies reflect an effort to maintain competitive advantage during late-stage clinical development and commercialization.
Research Collaborations
Patent applicants often engage in licensing agreements or collaborative R&D with biotech firms, academic institutions, or pharma companies to advance clinical trials.
Regulatory Pathways
The claims covering pharmaceutical formulations and delivery methods suggest the patent is strategically positioned for rapid progression through regulatory approvals, particularly if the compound shows promising pre-clinical data.
Key Takeaways
- U.S. Patent 11,752,094 claims a specific chemical compound, its derivatives, formulations, and therapeutic uses, with a broad scope designed to prevent third-party competition.
- The patent landscape indicates active filings and patent family expansion in major jurisdictions, optimizing global protection.
- The patent's scope encompasses composition, method of use, and formulation claims, making it a robust asset for the patent holder.
- The absence of patent challenges enhances prospects for market exclusivity.
- The strategic breadth of claims suggests a long-term commercialization plan, with potential for licensing or strategic alliances.
FAQs
1. How broad are the chemical claims in Patent 11,752,094?
They cover the key molecular scaffold with variants, salts, and isomers, creating a comprehensive shield against similar compounds with minor modifications.
2. Are there similar patents in other jurisdictions?
Yes. The patent family includes filings in Europe, China, and Japan, with similar claim scopes to ensure global protection.
3. What potential intervals could influence the patent's lifespan?
Legal extensions or patent term adjustments can extend exclusivity beyond 20 years from the filing date, potentially until 2045.
4. Is there evidence of infringement or litigation?
No publicly available infringement suits or invalidation cases as of now.
5. What are the key competitor activities?
Competitors are likely filing their own patents on similar compounds or alternative mechanisms within the same therapeutic areas, but the broad scope of this patent provides a significant barrier.
References
[1] USPTO Patent No. 11,752,094
[2] European Patent Office (EPO) patent filings
[3] Patent landscape reports for similar molecular classes
